Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 21;10:1393. doi: 10.3389/fimmu.2019.01393

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Chen, Liu, Chen, Hu, Zhang, Sun, Tang, Liu, Zhang, Ke, Wu and Chen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Ponatinib attenuates pro-inflammatory cytokines in the lungs of mice with lethal infection. Mice were infected as described in Figure 2. Starting with day 3, daily administration of placebo or ponatinib (15 mg/kg) was given orally. Inflammatory cytokine/chemokine concentrations in BALF from mice at day 5 and day 7 post-infection (n = 3 per group at each time point) were measured. (A) IL-6, IL-10, IL-12(P40), IL-12(P70), IL-17A, Eotaxin, G-CSF, KC, MCP-1, MIP-1a, MIP-1β, TNF-α, and CCL5 concentrations were quantified by multiplex assay and IP-10 concentrations were measured by AlphaLISA. IFN levels in (B) BALF and (C) serum were measured by ELISA. (D) Viral titers in BALF taken on day 5 and 7 post-infection were measured by TCID50 assay using MDCK cells (n = 3 per group at each time point). The data are representative of two independent experiments.*p < 0.05; **p < 0.01; ***p < 0.001.